Evercore ISI initiated coverage on Kailera Therapeutics
$KLRA
Biotechnology: Pharmaceutical Preparations
Health Care
Evercore ISI initiated coverage of Kailera Therapeutics with a rating of Outperform
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/12/2026 | $30.00 | Overweight | Analyst |
| 5/12/2026 | Outperform | William Blair | |
| 5/12/2026 | $36.00 | Outperform | Leerink Partners |
| 5/12/2026 | $57.00 | Buy | TD Cowen |
| 5/12/2026 | Outperform | Evercore ISI | |
| 5/12/2026 | $48.00 | Buy | Jefferies |
Analyst initiated coverage of Kailera Therapeutics with a rating of Overweight and set a new price target of $30.00
William Blair initiated coverage of Kailera Therapeutics with a rating of Outperform
Leerink Partners initiated coverage of Kailera Therapeutics with a rating of Outperform and set a new price target of $36.00
10-Q - Kailera Therapeutics, Inc. (0002096997) (Filer)
8-K - Kailera Therapeutics, Inc. (0002096997) (Filer)
SCHEDULE 13D - Kailera Therapeutics, Inc. (0002096997) (Subject)
In Phase 3 trial in obesity/overweight in China, HRS-7535 achieved a mean weight loss of up to 10.9% at Week 44 and a mean weight loss of up to 11.1% at Week 50 Kailera currently conducting global Phase 2 trial of KAI-7535 in obesity to further optimize KAI-7535's clinical profile for the treatment of obesityIn second Phase 3 trial in type 2 diabetes in China, HRS-7535 lowered HbA1c by an average of 1.50% to 1.68% across dosesLiver safety findings in both Phase 3 trials consistent with data generated to date; no liver safety signals observed WALTHAM, Mass., July 07, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (Kailera), a clinical-stage biotechnology company focused on elevating t
WALTHAM, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc., a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced the appointment of Kathleen Tregoning as Chief Corporate Affairs Officer. "We are delighted to welcome Kathleen to our leadership team as we advance our late-stage clinical trials in obesity and navigate the rapidly evolving obesity treatment landscape," said Ron Renaud, President and Chief Executive Officer of Kailera. "Kathleen is a seasoned executive with deep experience helping biopharmaceutical companies build trust, navigate complexity, and engage stakeholders around a shared mission. Her strategic per
Presentations will feature clinical results for ribupatide, a GLP-1/GIP receptor dual agonist being developed as a once-weekly injection and a once-daily oral pill for the treatment of obesity and overweightAdditional data from Phase 2 obesity clinical trial of ribupatide oral demonstrating mean weight loss of up to 12.1% with no observed plateau and up to 38.6% of participants achieving at least 15% weight loss at 26 weeks; incidence of gastrointestinal adverse events was low, with vomiting reported in 11.4% and 7.5% of participants taking 25 mg and 50 mg ribupatide oral, respectivelyPhase 1 single ascending dose trial, the first ribupatide injection clinical data generated outside of China
4 - Kailera Therapeutics, Inc. (0002096997) (Issuer)
3 - Kailera Therapeutics, Inc. (0002096997) (Issuer)
4 - Kailera Therapeutics, Inc. (0002096997) (Issuer)
WALTHAM, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc., a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced the appointment of Kathleen Tregoning as Chief Corporate Affairs Officer. "We are delighted to welcome Kathleen to our leadership team as we advance our late-stage clinical trials in obesity and navigate the rapidly evolving obesity treatment landscape," said Ron Renaud, President and Chief Executive Officer of Kailera. "Kathleen is a seasoned executive with deep experience helping biopharmaceutical companies build trust, navigate complexity, and engage stakeholders around a shared mission. Her strategic per